Skip to main content

Table 1 Demographic and baseline data in the randomised set.

From: Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial

 

IM Group

N= 374

SC Group

N= 378

Age at vaccination, months ± SD

13.8 ± 1.7

13.7 ± 1.6

Male, n (%)

206 (55.1)

210 (55.6)

Weight, kg ± SD

10.1 ± 1.2

10.2 ± 1.3

Height, cm ± SD

77.2 ± 3.6

77.4 ± 3.4

Seronegative, n (%)1

  

   Measles (<255 mIU/ml)

364 (97.3)

371 (98.1)

   Mumps (<10 ELISA Ab units/ml)

364 (97.3)

370 (97.9)

   Rubella (<10 IU/ml)

335 (89.6)

324 (85.7)

   Varicella (<1.25 gpELISA units/ml)

352 (94.1)

353 (93.4)

  1. (IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route).
  2. 1 It is not possible to calculate the seropositive rates directly from these data because of the missing values; overall 5 (0.7%) subjects were seropositive at baseline for measles, 11 (1.5%) for mumps, 81 (10.8%) for rubella and 37 (4.9%) for varicella
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us